

Electronic Supplementary Information

Table S1. Screening of pharmaceutical acceptable components to obtain the most appropriate solid lipid/surfactant combination.

		Surfactant				
		Pluroni F68	Pluronic F127	Tween 20	Tween 85	
Solid lipid	SS	Size (nm)	165,6 ± 2,8	150,7 ± 0,8	185,8 ± 1,3	254,8 ± 2,0
		z-pot (mV)	-15,03	-19,81	-37,23	-33,15
		PDI	0,125	0,124	0,111	0,138
	CP	Size (nm)	172,5 ± 1,2	159,9 ± 1,1	157,1 ± 1,3	147,4 ± 1,1
		z-pot (mV)	-27,22	-23,18	-33,59	-29,74
		PDI	0,097	0,131	0,202	0,183
	MM	Size (nm)	192,3 ± 1,5	159,1 ± 1,0	160,6 ± 1,0	152,5 ± 1,9
		z-pot (mV)	-30,14	-19,71	-31,62	-31,94
		PDI	0,173	0,146	0,164	0,153
	SA	Size (nm)	484,9 ± 9,8	350,3 ± 5,1	580,7 ± 19,8	370,5 ± 4,3
		z-pot (mV)	-29,31	-24,19	-26,37	-31,61
		PDI	0,279	0,093	0,279	0,153

Table S2: Randomize central composite design with runs and experimental responses in their original coding.

Run	X ₁	X ₂	X ₅	d	PDI	Z pot
1	568.18	4.00	70.00	197.8	0.198	-8.06
2	300.00	5.00	80.00	201.0	0.219	-2.31
3	300.00	3.00	80.00	209.2	0.231	-6.13
4	300.00	3.00	60.00	198.5	0.228	-4.92
5	400.00	4.00	70.00	203.0	0.187	-6.27
6	400.00	4.00	53.18	197.3	0.203	-6.66
7	500.00	3.00	60.00	186.9	0.218	-12.7
8	400.00	4.00	86.82	209.7	0.213	-7.35
9	400.00	4.00	70.00	207.7	0.213	-5.74
10	500.00	5.00	80.00	200.3	0.193	-5.50
11	400.00	4.00	70.00	204.3	0.199	-6.04
12	231.82	4.00	70.00	201.0	0.194	-3.76
13	300.00	5.00	60.00	192.5	0.196	-3.29
14	400.00	4.00	70.00	203.2	0.225	-4.45
15	400.00	4.00	70.00	205.7	0.219	-2.03
16	400.00	5.68	70.00	194.5	0.192	-3.15
17	400.00	2.32	70.00	205.1	0.237	-6.50
18	500.00	5.00	60.00	199.1	0.198	-3.96
19	500.00	3.00	80.00	204.1	0.268	-7.75

Figure SM1. Corresponding plots showing cell populations at each quadrant after the different treatments

